0000000000098235

AUTHOR

Antonino Galuffo

Ipertermia e chemioterapia nel tumore vescicale superficiale a medio rischio di recidiva:esperienza preliminare

research product

Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica.

research product

FOLLOW UP A LUNGO TERMINE DI PAZIENTI CON POSITIVITA’ DELLA NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA

research product

TERAPIA DI II LINEA NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC) CON ESTRAMUSTINA FOSFATO ED ETOPOSIDE. STUDIO DI FASE II DEL GSTU

research product

A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors

INTRODUCTION AND OBJECTIVE: The possible role of gemcitabine inintravesical therapy of superficial transitional cell carcinoma of the bladder (TCCB) has been suggested. The European Organization for Research and Treatment of Cancer Urological Group validated the use of papillary marker lesion left in the bladder after TUR as the best tool to measure the efficacy of a drug by intravesical route against TCCB. The rsults on 27 patients are herein presented. METHODS: Twenty-seven patients, with recurrent superficial TCCB (Ta-T1, G1-G2), were treated with intravesical gemcitabine for 1 to 3 papillary marker lesions (5-15 mm) left unreseacted after TUR. Twenty-one patients (78%) had recurrent tum…

research product

Intravesical gemcitabine in superficial bladder tumors. Results of a phase I-II study

the good tolerability of intravesical gemcitabine have been recently published. The evaluation of the activity on a papillary marker lesion is the best tool to measure the efficacy of a drug by intravesical route against superficial transitional cell carcinoma of the bladder (TCCB). The scientific background and the ethical acceptability of this approach have been validated by the European Organization for Research and Treatment of Cancer Urological Group. The aim of the present study was to evaluate the ablative efficacy of weekly intravesical instillations of gemcitabine against a histologically proven papillary marker lesion. MATERIAL & METHODS: Twenty-seven patients, affected by recurre…

research product

La terapia dei tumori vescicali superficiali: lo stato attuale

research product

Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study

-

research product

ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU)

-

research product

Ruolo della terapia di mantenimento e fattori di rischio ambientale nel carcinoma vescicale superficiale. Pazienti sottoposti a chemioterapia endovescicale adiuvante. Risultati preliminari di uno studio randomizzato su 577 pazienti.

research product

Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU).

research product

PSA E PROSTATITE CRONICA CLINICAMENTE SILENTE IN PZ CON SOSPETTO CARCINOMA PROSTATICO T1C

research product

Risultati a lungo termine del trattamento con TUR e terapia endovescicale adiuvante nell’urotelioma vescicale T1G3. Recidiva, progressione e sopravvivenza in 236 pazienti

research product

IS IT POSSIBLE TO PREDICT CHEMORESISTANCE OF SUPERFICIAL BLADDER CARCINOMA?

research product

Prostatite clinicamente silente (INH IV) ed elevazione del PSA.

research product

ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO ED ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO. STUDIO RANDOMIZZATO IN FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU)

research product

La p53 nel tumore vescicale superficiale (Ta-T1, G1-3)

research product

LA RIDUZIONE DEL PSA DOPO TERAPIA ANTIBIOTICA NON HA VALORE PREDITTIVO IN SOGGETTI CANDIDATI ALLA AGOBIOPSIA PER SOSPETTO TUMORE PROSTATICO T1C

research product

POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE?

research product

Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder.

OBJECTIVE: Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder. METHODS: Tumor number, dimension, G-grade, T-stage, recurrences, cigarette smoking and water supply were recorded in patients harboring Ta-T1 G1-3 transitional cell carcinoma of the bladder. RESULTS: Of 577 patients, 61% had multiple and 36% recurrent tumors. Two hundred and forty-one patients (42%) were current smokers and 188 (33%) were former smokers. Bottled water was the only drinkable source for 249 (45%) patients, municipal water supply for 177 (32%), artesian wells for 38 (7%), spring water for 7 (1%) and mixed source for 89 (…

research product

Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1.

research product

Ipertermia e chemioterapia nel tumore vescicale superficiale a medio-alto rischio:esperienza preliminare sulla tollerabilità.

research product

low dose oral chemotherapy for hormone refractory prostate carcnoma.Estramustine phosphate versus estramustine phosphate and etoposide. A randomised phase II study of GSTU Found.

research product

Role of antimicrobial tratment in patients with elevated PSA and normal digital rectal examination.

research product

Risultati di uno studio pilota di fase I-II con gemcitabina endovescicale nel tumore vescicale superficiale (TA-T1)

research product

Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione –

-

research product

INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY

research product

Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine

research product

TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI

research product

Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica

research product